Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate-Reference-Cited by-同舟云学术

Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate

Published:2012-08 Issue:313 Volume:96 Page:40-43
ISSN:1286-0115
Container-title:Morphologie
language:en
Short-container-title:Morphologie

Author:

Hoppé E.,Masson C.,Laffitte A.,Chappard D.,Audran M.

Publisher

Elsevier BV

Subject

Anatomy

Reference19 articles.

1. Bisphosphonates in bone diseases. From the laboratory to the patient.;Fleisch,2000

2. Mechanisms of action of etidronate and other bisphosphonates;Ebetino;Rev Contemp Pharmacother,1998

3. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis;Storm;J Bone Miner Res,1993

4. Treatment of Paget's disease of bone with ethane-1, hydroxy-1,1 diphosphonate (EHDP) at a low dosage (5mg/kg/day);Alexandre;Clin Orthop Relat Res,1983

5. Diphosphonates in Paget's disease;Russell;Lancet,1974

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role and Regulation of Transcription Factors in Osteoclastogenesis;International Journal of Molecular Sciences;2023-11-10

2. Principles of Diagnosis and Treatment of Osteomalacia;Clinical Foundations of Musculoskeletal Medicine;2021

3. Molecular Mechanisms and Emerging Therapeutics for Osteoporosis;International Journal of Molecular Sciences;2020-10-15

4. Role of Phosphate in Biomineralization;Calcified Tissue International;2020-07-25

5. MPMBP down-regulates Toll-like receptor (TLR) 2 ligand-induced proinflammatory cytokine production by inhibiting NF-κB but not AP-1 activation;International Immunopharmacology;2020-02